Evidence map›Paper›PMID 29560096›Full record

ArticleOncotarget2018

Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer.

Chey Loveday, Kevin Litchfield, Max Levy, Amy Holroyd, Peter Broderick, Zsofia Kote-Jarai, Alison M Dunning, Kenneth Muir, Julian Peto, Rosalind Eeles and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression.Journal of experimental & clinical cancer research : CR · 2025
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Chey LovedayDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Kevin LitchfieldDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Max LevyDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Amy HolroydDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Zsofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Alison M DunningCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Kenneth MuirDivision of Health Sciences, Warwick Medical School, Warwick University, Warwick, UK.
Julian PetoDepartment of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Rosalind EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Darshna DudakiaDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Nick OrrThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Nora PashayanDepartment of Applied Health Research, University College London, London, UK.
Alison ReidAcademic Uro-oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
Robert A HuddartAcademic Radiotherapy Unit, Institute of Cancer Research, Sutton, Surrey, UK.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Clare TurnbullDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Institute of Cancer Research · GBRoyal Marsden NHS Foundation Trust · GBUniversity of Cambridge · GBBreast Cancer Now · GBLondon School of Hygiene & Tropical Medicine · GBThe Francis Crick Institute · GBUniversity College London · GBUniversity of Manchester · GB

Funding

Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Imputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9M
Cancer Research UK 10118Cancer Research UK 15007Cancer Research UK 16563Cancer Research UK 17528Medical Research Council G0700491NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008IWellcome Trust
6 · The paper itself

Abstract

Testicular germ cell tumor (TGCT), the most common cancer in men aged 18 to 45 years, has a strong heritable basis. Genome-wide association studies (GWAS) have proposed single nucleotide polymorphisms (SNPs) at a number of loci influencing TGCT risk. To further evaluate the association of recently proposed risk SNPs with TGCT at 2q14.2, 3q26.2, 7q36.3, 10q26.13 and 15q21.3, we analyzed genotype data on 3,206 cases and 7,422 controls. Our analysis provides independent replication of the associations for risk SNPs at 2q14.2 (rs2713206 at

Indexed as

germ cell tumorGWASoncoarraytesticular cancerTGCT

Identifiers

PMID29560096
PMCPMC5849160
OpenAlexW2773945625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.